Welcome to LookChem.com Sign In|Join Free

CAS

  • or

1237526-35-0

Post Buying Request

1237526-35-0 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

1237526-35-0 Usage

General Description

1-Piperidinecarboxylic acid, 4-(aMinoMethyl)-3-fluoro-, 1,1-diMethylethyl ester, (3R,4S)-rel is a chemical compound with the molecular formula C13H23FN2O2. It is commonly used as a building block in the synthesis of pharmaceuticals and biologically active compounds. It is an ester derivative of 4-aminomethyl-3-fluoropiperidinecarboxylic acid, and its three-dimensional structure is characterized by the (3R,4S) configuration. This chemical has shown potential as a synthetic intermediate in the development of new drugs and is of interest to researchers in the pharmaceutical industry. Further study and research are required to fully understand the potential applications and uses of this compound.

Check Digit Verification of cas no

The CAS Registry Mumber 1237526-35-0 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,2,3,7,5,2 and 6 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 1237526-35:
(9*1)+(8*2)+(7*3)+(6*7)+(5*5)+(4*2)+(3*6)+(2*3)+(1*5)=150
150 % 10 = 0
So 1237526-35-0 is a valid CAS Registry Number.

1237526-35-0Downstream Products

1237526-35-0Relevant articles and documents

BICYCLIC AZAHETEROCYCLIC COMPOUNDS AS NR2B NMDA RECEPTOR ANTAGONISTS

-

, (2016/07/05)

Disclosed are chemical entities of Formula (I): wherein R1 and Z are defined herein, as NR2B subtype selective receptor antagonists. Also disclosed are pharmaceutical compositions comprising a chemical entity of Formula (I), and methods of treating various diseases and disorders associated with NR2B antagonism, e.g., diseases and disorders of the CNS, such as depression, by administering a chemical entity of Formula (I).

Radiolabelling of 1,4-disubstituted 3-[18F]fluoropiperidines and its application to new radiotracers for NR2B NMDA receptor visualization

Koudih, Radouane,Gilbert, Gwenaelle,Dhilly, Martine,Barre, Louisa,Debruyne, Daniele,Sobrio, Franck,Abbas, Ahmed

supporting information, p. 8493 - 8500,8 (2012/12/12)

In order to develop a novel and useful building block for the development of radiotracers for positron emission tomography (PET), we studied the radiolabelling of 1,4-disubstituted 3-[18F]fluoropiperidines. Indeed, 3-fluoropiperidine became a useful building block in medicinal chemistry for the pharmacomodulation of piperidine-containing compounds. The radiofluorination was studied on substituted piperidines with electron-donating and electron-withdrawing N-substituents. In the instance of electron-donating N-substituents such as benzyl or butyl, configuration retention and satisfactory fluoride-18 incorporation yields up to 80% were observed. In the case of electron-withdrawing N-substituents leading to carbamate or amide functions, the incorporation yields depend on the 4-susbtitutent (2 to 63%). The radiolabelling of this building block was applied to the automated radiosynthesis of NR2B NMDA receptor antagonists and effected by a commercially available radiochemistry module. The in vivo evaluation of three radiotracers demonstrated minimal brain uptakes incompatible with the imaging of NR2B NMDA receptors in the living brain. Nevertheless, moderate radiometabolism was observed and, in particular, no radiodefluorination was observed which demonstrates the stability of the 3-position of the fluorine-18 atom. In conclusion, the 1,4-disubstituted 3-[18F]fluoropiperidine moiety could be of value in the development of other radiotracers for PET even if the evaluation of the NR2B NMDA receptor antagonists failed to demonstrate satisfactory properties for PET imaging of this receptor.

2′ Biaryl amides as novel and subtype selective M1 agonists. Part II: Further optimization and profiling

Budzik, Brian,Garzya, Vincenzo,Shi, Dongchuan,Walker, Graham,Lauchart, Yann,Lucas, Adam J.,Rivero, Ralph A.,Langmead, Christopher J.,Watson, Jeannette,Wu, Zining,Forbes, Ian T.,Jin, Jian

supporting information; scheme or table, p. 3545 - 3549 (2010/08/22)

Further optimization of the biaryl amide series via extensively exploring structure-activity relationships resulted in potent and subtype selective M 1 agonists exemplified by compounds 9a and 9j with good rat PK properties including CNS penetration. Synthesis, structure-activity relationships, subtype selectivity for M1 over M2-5, and DMPK properties of these novel compounds are described.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 1237526-35-0